Novartis

Novartis
Fabrikstrasse 2, 4056 Basel
Novartis  
Discipline: Medicine/Pharmacology
Related:

Research & Development at Novartis The Novartis Pharmaceuticals clinical pipeline holds a broad stream of 140 future projects including both new molecular entities and additional indications or formulations for marketed products. Our pipeline has consistently being ranked by experts as one of the strongest in the industry. Our scientists focus on diseases for which medical need remains unmet and strive to improve the drug discovery process with an approach that integrates novel concepts and tools across multiple disease areas.

#display_name

Pharmacology - Jul 11
After review of clinical data from the Generation Program studies, the sponsors concluded that the potential benefit for participants taking CNP520 no longer outweighs the risk Basel, July 11, 2019 - Novartis, Amgen and Banner Alzheimer's Institute today announced the decision to discontinue investigation of the BACE1 inhibitor CNP520 (umibecestat) in two pivotal Phase II/III studies in the Alzheimer's Prevention Initiative Generation Program.
Health - Jul 2

Sandoz gefitinib indicated for adult patients with locally advanced or metastatic non-small cell lung cancer with activating mutations of EGFR-TK More than 300,000 European men and women are diagnosed with lung cancer annually, making it the fourth most common cancer With launch Sandoz builds on

Pharmacology - Jul 1

Basel, July 1, 2019 - Novartis today announced that it has completed its acquisition of Xiidra (lifitegrast ophthalmic solution) 5%, the first and only prescription treatment approved to treat both signs and symptoms of dry eye by inhibiting inflammation caused by the disease.

Pharmacology - Jul 1

Data from LIBERTY demonstrated sustained efficacy of Aimovig (erenumab) 140 mg in reducing monthly migraine days (MMD) at 13-24 weeks in episodic migraine patients with 2-4 prior preventive treatment failures -   At week 24, patients on Aimovig experienced a sustained reduction in physical impair

Health - Jun 17

For the first time efficacy and safety data from dedicated phase III trials are analyzed together in one abstract, backing Cosentyx as comprehensive treatment across multiple manifestations of psoriatic disease and ankylosing spondylitis -   The abstract presented at the World Congress of Dermato

Health - Jun 14

Results from two Phase II trials, ENESTfreedom and ENESTop, support and extend previous findings of long-term durability of molecular response after stopping Tasigna, reducing time on drug for many CML patients 1,2 -   New Phase I data for asciminib in combination with imatinib, nilotinib or dasa

Pharmacology - Jul 2

Data presented again at European Academy of Neurology (EAN) congress show that baseline neurofilament light chain (NfL) levels can predict cognitive impairment and disability worsening in secondary progressive MS (SPMS) patients, supporting the use of blood NfL levels as a biomarker -   EXPAND da

Pharmacology - Jul 1

Data from the active treatment phase of STRIVE investigated efficacy and safety of Aimovig (erenumab) 70 and 140 mg in episodic migraine patients with prior preventive treatment failures -   STRIVE data show that 55% of patients on Aimovig 140 mg experienced at least a 50% reduction in the number

Health - Jun 26

New data show that Cosentyx modulates gene expression leading to substantial improvement of inflammation, as early as Week 12 by reversing plaque histopathology in the majority of patients -   The results show that the IL-17A antibody Cosentyx induces also a rapid and sustained suppression of add

Health - Jun 14

Data show switching to Hyrimoz (biosimilar adalimumab) from the reference medicine provides sustained efficacy with no new safety concerns in patients with moderate-to-severe rheumatoid arthritis -   ADMYRA data reinforces review summarizing 90+ publications, that switching from reference biologi

Health - Jun 13

New European data from IMAS survey show that people living with axial spondyloarthritis (axSpA) suffer a delay in diagnosis of over 7 years, potentially leading to an increase in work-related issues due to worsening disease burden -   The experience of people living with axSpA, a long-term inflam




website preview

Link

Medicine and Life Sciences